Hookipa Pharma Inc
NASDAQ:HOOK
Regulatory, Earnings Announcements
Hookipa Pharma Inc Announces Positive Interim Phase 1 Data On HB-201, Its Replicating Monotherapy For Treatment Of HPV16(+) Cancers
Published: 12/07/2020 11:24 GMT
Hookipa Pharma Inc (HOOK) - Hookipa Pharma Inc - Announced Positive Interim Phase 1 Data on Hb-201, Its Replicating Monotherapy for Treatment of Hpv16(+) Cancers.
Hookipa Pharma Inc - Results Support First Proof of Concept for Hookipa's Replicating Investigational Single-vector Immunotherapy in Oncology.
Hookipa Pharma Inc - Median Progression-free Survival (mpfs) is Currently Measured at 72 Days and is Ongoing.
Hookipa Pharma Inc - of 22 Patients Enrolled on Trial As of December 4(th), Preliminary Safety Data Show That Hb-201 Has Been Well Tolerated.
Hookipa Pharma Inc - Treatment-related Adverse Events Were Reported by 41% of Participants.
Hookipa Pharma Inc - Almost All Reported Events Were Grade 1 and 2 and Included Fatigue, Fever, Decreased Appetite, Constipation, Nausea, and Itching.
Hookipa Pharma Inc - Only One Serious Adverse Event Deemed Related to Hb-201, Grade 3 Fatigue Leading to Hospitalization, Has Been Reported to Date.
Hookipa Pharma Inc - Results Support First Proof of Concept for Hookipa's Replicating Investigational Single-vector Immunotherapy in Oncology.
Hookipa Pharma Inc - Median Progression-free Survival (mpfs) is Currently Measured at 72 Days and is Ongoing.
Hookipa Pharma Inc - of 22 Patients Enrolled on Trial As of December 4(th), Preliminary Safety Data Show That Hb-201 Has Been Well Tolerated.
Hookipa Pharma Inc - Treatment-related Adverse Events Were Reported by 41% of Participants.
Hookipa Pharma Inc - Almost All Reported Events Were Grade 1 and 2 and Included Fatigue, Fever, Decreased Appetite, Constipation, Nausea, and Itching.
Hookipa Pharma Inc - Only One Serious Adverse Event Deemed Related to Hb-201, Grade 3 Fatigue Leading to Hospitalization, Has Been Reported to Date.
Revenue is expected to be $4.39 Million
Adjusted EPS is expected to be -$0.23
Next Quarter Revenue Guidance is expected to be $4.39 Million
Next Quarter EPS Guidance is expected to be -$0.22
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.23
Next Quarter Revenue Guidance is expected to be $4.39 Million
Next Quarter EPS Guidance is expected to be -$0.22
More details on our Analysts Page.